VirtualScopics Alliance Update

RNS Number : 4408R

IXICO plc

29 June 2015

 



IXICO and VirtualScopics Alliance Update

Award of Two New Clinical Trial Contracts - in Oncology and Neurodegenerative Disease

29 June 2015, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announced that together with its alliance partner, VirtualScopics, Inc. (Ticker: VSCP) ('VirtualScopics'), it has been awarded contracts with two top 15 pharmaceutical companies, one in metastatic solid tumours and one in a rare neurodegenerative disease.  IXICO's TrialTracker™ digital platform will be deployed in both studies to collect and manage imaging data and in the neurodegeneration study, IXICO's Assessa® digital technology will be used to analyse MRI data collected from patients.

The metastatic solid tumour study will make use of VirtualScopics extensive expertise applying FDG-PET (Fludeoxyglucose PET) to measuring disease progression in oncology and will involve working with imaging centres across North America and Europe.  The study is expected to complete in June 2017.

The neurodegeneration study will make use of IXICO's expertise in structural MRI and will involve IXICO working with key opinion leaders across specialist imaging centres throughout North America.  As part of this contract, IXICO's Assessa® medical device will utilise its proprietary LEAP methodology to quantify disease pathology in brain regions that are particularly relevant to measuring disease progression and will be applied to MRI data collected from subjects enrolled in the study.  The study is expected to complete in January 2018.

Professor Derek Hill, Chief Executive Officer of IXICO, commented:  "Our alliance with VirtualScopics continues to be valued by our pharmaceutical partners as we support their clinical trials on a global basis, as evidenced by these two new contract wins.  Our TrialTracker™ digital platform provides customers with digital technology combined with operational effectiveness.  Furthermore, our involvement with the neurodegenerative disease study demonstrates our ability to broaden our therapeutic expertise and validates the importance of IXICO's technology across a range of brain diseases."

Eric Converse, Chief Executive Officer of VirtualScopics commented:  "Winning these two recent studies with IXICO clearly demonstrates the strength of our alliance.  We are bringing a viable, stronger imaging choice to the risk averse pharmaceutical industry.  The list of studies on TrialTracker™ within VirtualScopics continues to grow with increased momentum.  Customers are very pleased with this option.  TrialTracker™ is the backbone of our relationship with IXICO and allows us to fully exploit our collaborative offering."

Enquiries:

IXICO plc	[phone]
Derek Hill, CEO
Susan Lowther, CFO
Charles Spicer, VP Corporate Development
Peel Hunt LLP (Nominated Adviser and Broker)	[phone]
James Steel
Clare Terlouw
Daniel Stewart & Company (Joint Broker)	[phone]
Martin Lampshire
David Coffman
FTI Consulting Limited (Investor Relations)	[phone]
Simon Conway
Mo Noonan
Matthew Moss

Notes to Editors

About IXICO

IXICO, the brain health company, uses its innovative and proprietary digital health technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes.  IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including Alzheimer's disease, Huntington's disease, other causes of dementia and Multiple Sclerosis. 

Assessa®

IXICO's digital platform technology which can combine imaging, demographic, cognitive and functional information to improve the precision of patient stratification, differential diagnosis and predict likely disease progression of dementia and other neurodegenerative diseases.  Available in both research and medical device forms, Assessa® can support both stratification of patients in clinical trials and diagnosis of disease in the clinic. 

More information is available on www.ixico.com.

About VirtualScopics

VirtualScopics, Inc. (NASDAQ:VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development.  For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly-accepted services provided by other clinical trial imaging providers.  Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, everyday clinical trial imaging services.

For more information on VirtualScopics, Inc. please visit www.virtualscopics.com.

The IXICO VirtualScopics Alliance

This alliance provides the clinical trials industry with global operational capabilities and a full range of therapeutic areas and modality expertise.  The alliance enhances both companies' abilities to deliver world-class services to pharmaceutical, biotech and academic customers and collaborators around the globe.

 

END

 

 

CNTEAFKPAAFSEAF